secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001558370-23-016113
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem reports 42% ORR in FRAME study for avutometinib/defactinib in LGSOC
----------------------------------------------------------------------------

- Overall response rate 42% (11/26) in evaluable recurrent LGSOC patients.
- ORR 58% in KRAS mutant LGSOC (7/12) vs 33% in KRAS wild-type (4/12).
- Median duration of response 26.9 months; median PFS 20.0 months.
- 19% of patients (5/26) remained on treatment at data cutoff, minimum 17 months follow-up.
- RAMP 201 Part A confirmed 45% ORR by independent review reported at ASCO 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000155837023016113/0001558370-23-016113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000155837023016113/vstm-20230928x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer